0001209191-23-050332.txt : 20230921 0001209191-23-050332.hdr.sgml : 20230921 20230921210203 ACCESSION NUMBER: 0001209191-23-050332 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230920 FILED AS OF DATE: 20230921 DATE AS OF CHANGE: 20230921 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Liptak Len CENTRAL INDEX KEY: 0001956842 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41567 FILM NUMBER: 231270087 MAIL ADDRESS: STREET 1: 124 SUNHAVEN RD CITY: DANVILLE STATE: CA ZIP: 94506 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ProSomnus, Inc. CENTRAL INDEX KEY: 0001934064 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5675 GIBRALTAR AVENUE CITY: PLEASANTON STATE: CA ZIP: 94588 BUSINESS PHONE: 844-537-5337 MAIL ADDRESS: STREET 1: 5675 GIBRALTAR AVENUE CITY: PLEASANTON STATE: CA ZIP: 94588 FORMER COMPANY: FORMER CONFORMED NAME: LAAA Merger Corp. DATE OF NAME CHANGE: 20220615 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-09-20 0 0001934064 ProSomnus, Inc. OSA 0001956842 Liptak Len 5675 GIBRALTAR AVENUE PLEASANTON CA 94588 1 1 0 0 Chief Executive Officer 0 Series A Preferred Stock 1.00 2023-09-20 4 A 0 50 A 2023-09-20 Common Stock 50000 50 D Warrants (right to buy) 1.00 2023-09-20 4 A 0 50000 A 2028-09-20 Common Stock 50000 50000 D The Series A Preferred Stock is convertible (subject to certain conversion limitations prior to the Issuer obtaining stockholder approval of the transactions contemplated by the SPA) into Common Stock at the Reporting Person's election at $1 per share, which conversion price may be adjusted in accordance withe the terms of the Series A Preferred Stock, and has no expiration date. The Reporting Person acquired the shares and warrants pursuant to the terms of that certain Securities Purchase Agreement by and among the Issuer and the investors named therein, as disclosed in the Current Report on Form 8-K filed by the Issuer with the SEC on September 21, 2023 (the "SPA"). The warrants become exercisable upon the Issuer obtaining shareholder approval of the transactions contemplated by the SPA. /s/ Brian B. Dow, Attorney-in-fact 2023-09-21